

Cancer Immunomodulators Market & Pipeline Insight 2020

<https://marketpublishers.com/r/C3CB190F60FEN.html>

Date: June 2015

Pages: 1000

Price: US\$ 2,000.00 (Single User License)

ID: C3CB190F60FEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Immune system has developed myriad of techniques for preventing progression and proliferation of infectious diseases in the body. Different immunocytes vary in qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of immunomodulators. They could be natural occurring or synthetically derived molecule used for modulating activities of immune system. Immunomodulators have ability to augment or reduce immune reactions depending upon nature of ailment. In their presence, immune system produces those molecules which increase the rate of reaction and increases immunity. On the other hand, these molecules may reduce the effect of immune system in order to alleviate the patients' medical condition.

Investigators have been able to identify their clinical applicability in various diseases due to which various immunomodulator based products are entering in global market. They are continuously changing due to which they may be tweaked according to medical necessity. Owing to multiple effects on immune system, sometimes they may be observed in overlapping drug categories. Immunomodulators present in body may undergo biochemical and biophysical changes and become overactive to target own components. This case has been widely observed in autoimmune diseases where multiple issues appear without any apparent reasons. On the other hand, effective defense against removal of cancerous cells is lost due to which pharmacological preparation has to be administered. Immunomodulators are widely used in these and other categories as they proved to have superior pharmacological efficacy along with minimum adverse effects.

Immunomodulators can bring changes in immune system due to which changes in immunochemistry are observed and they could be customized to alter programming of immune system. As a result, pharmacological benefits of immunomodulators are being explored by investigators in clinical trials. Their oncological applications are being studied and various drug candidates are at different stages of clinical trials which would be commercialized in coming years. New modalities are also being discovered by investigators to increase the potency, long-term cancer remission and administration in various cancer indications. In this way, cancer immunomodulators are expected to offer better medical care to cancer patients. Few immunomodulators drugs for various cancer indications have been introduced in market and they are also expected to increase number in coming years.

Demand for novel immunomodulators having higher pharmacological benefits is escalating rapidly across the globe. Pharmaceutical companies have recognized their marketing potential of due to which higher investments are being made in research and development category. They are highly compatible in nature and easily customized due to which they could be designed according to the necessities of drug development program. Moreover, their clinical pipeline is expected to become strong due to increased rate of innovations. In coming years, new immunomodulators would be available in market that would be able to fulfill the high unmet medical demand. Increasing cancer incidences has created burgeoning pressure on pharmaceutical companies to introduce them promptly in global market. Their development may take time which is expected to be solved by technological advancements and increased knowledge about their mechanisms.

'Cancer Immunomodulators Market & Pipeline Insight 2020' Report Highlights:

Introduction & Need of Cancer Immunomodulators

Cancer Immunomodulators Mechanism

Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase

Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs

Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight

Marketed Cancer Immunomodulators: 47

Cancer Immunomodulators Drug Patent Analysis

Contents

1. INTRODUCTION TO CANCER IMMUNOMODULATORS

2. CANCER IMMUNOMODULATORS MECHANISM

3. NEED FOR IMMUNOMODULATORS IN CANCER THERPAY

4. GLOBAL CANCER IMMUNOMODULATORS MARKET OVERVIEW

4.1 Current Market Scenario

4.2 Cancer Immunomodulators Clinical Pipeline Analysis

5. CANCER IMMUNOMODULATORS MARKET FAVORABLE PARAMETERS

5.1 Research & Development

5.2 Escalating Cancer Incidences

5.3 Advances in Recombinant DNA Technology

5.4 Identification of New Pathways

5.5 Demand for Better Therapeutics

6. CANCER IMMUNOMODULATORS MARKET CHALLENGES

7. CANCER IMMUNOMODULATORS MARKET FUTURE OUTLOOK

8. CANCER IMMUNOMODULATORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

8.1 Unknown

8.2 Research

8.3 Preclinical

8.4 Clinical

8.5 Phase-I

8.6 Phase-I/II

8.7 Phase-II

8.8 Phase-II/III

8.9 Phase-III

8.10 Preregistration

8.11 Registered

9. MARKETED CANCER IMMUNOMODULATORS CLINICAL INSIGHT

10. COMPETITIVE LANDSCAPE

- 10.1 3M Pharmaceuticals
- 10.2 AbGenomics Corporation
- 10.3 Advaxis
- 10.4 Amgen
- 10.5 ANI Pharmaceuticals
- 10.6 Argos Therapeutics
- 10.7 AVAX Technologies
- 10.8 Baxter International
- 10.9 Biosidus
- 10.10 Biovest International
- 10.11 Bristol Myers Squibb
- 10.12 Celgene Corporation
- 10.13 Curadev
- 10.14 GlaxoSmithKline
- 10.15 Gradalis
- 10.16 Incyte
- 10.17 Intas Biopharmaceuticals
- 10.18 iTeos Therapeutics
- 10.19 Kyorin Pharmaceutical
- 10.20 Liponova
- 10.21 MedImmune
- 10.22 Merck
- 10.23 Mologen
- 10.24 NewLink Genetics Corporation
- 10.25 Northwest Biotherapeutics
- 10.26 Novartis
- 10.27 Peregrine Pharmaceuticals
- 10.28 Pfizer
- 10.29 Reliance Life Sciences
- 10.30 Roche
- 10.31 Sanofi
- 10.32 Toray
- 10.33 Vaccinogen

LIST OF FIGURE

- Figure 1-1: Functions of Immunomodulators
- Figure 1-2: Benefits of Immunomodulators
- Figure 1-3: Limitations of Immunomodulators
- Figure 2-1: Mechanism of Thalidomide
- Figure 2-2: Mechanism of Lenalidomide In Vivo
- Figure 2-3: Mechanism of Lenalidomide In Vitro
- Figure 2-4: Mechanism of Pomalidomide
- Figure 2-5: Mechanism of IDO Inhibitor
- Figure 2-6: Mechanism of TDO Inhibitor
- Figure 2-7: Mechanism of dSLIM immunomodulator
- Figure 4-1: Global Immunomodulators Market (US\$ Billion), 2014-2020
- Figure 4-3: Cancer Immunomodulators Pipeline by Phase (%), 2015
- Figure 4-4: Cancer Immunomodulators Pipeline by Phase (Number), 2015
- Figure 5-1: Cancer Immunomodulators Market Favorable Parameters
- Figure 5-2: Cancer Immunomodulators Market Challenges
- Figure 9-1: AbGenomics-Clinical Pipeline
- Figure 9-2: Argos Therapeutics Clinical Pipeline
- Figure 9-3: Gradalis Clinical Pipeline

I would like to order

Product name: Cancer Immunomodulators Market & Pipeline Insight 2020

Product link: <https://marketpublishers.com/r/C3CB190F60FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3CB190F60FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970